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1 SUMMARY 
 
The parasympathetic regulation of the heart may change in diseased states like congestive heart 
failure (CHF). In a functional study, a carbachol induced increased inotropic effect of muscarinic 
acetylcholine receptors (mAChRs) has been demonstrated in rats with CHF. The present study 
was undertaken to look for possible changes in mAChRs in CHF compared to normal cardiac 
ventricular membranes in rats.  
 
Congestive heart failure was induced in male Wistar rats by coronary artery ligation. 
Corresponding Sham groups were prepared and served as control group. After 6 weeks, the 
ventricles from non-failing and failing hearts were isolated. In addition ventricles from normal, 
non-operated rats were isolated. Receptor binding experiments were performed in the 
corresponding myocardium.  
 
No significant changes in the affinity of the radioligand, [3H]QNB, for the mAChRs were 
observed in the ventricles from CHF rats compared to Sham rats (Kd value of 0.15 ± 0.04 nmol/L 
in CHF rats and 0.18 ± 0.06 in Sham rats). A tendency of increase in the mAChR density in CHF 
rats compared to Sham rats was obtained, but the increase was not significant (Bmax of 175 ± 18 
fmol/mg protein in CHF rats and 139 ± 11 fmol/mg protein in Sham). mAChRs possessed high- 
and low affinity binding sites for the non-selective agonist, carbachol, in the absence of 
guanosine trisphosphate (GTP). There were no significant differences in the affinity between 
normal, Sham and CHF rats. In the presence of GTP, a shift in affinity to a higher concentration 
of agonist was observed in normal, Sham and to a lesser extent in CHF rats. This indicated a 
lower sensitivity to guanine nucleotides of mAChRs in CHF rats. The mAChR subtype profile 
was characterised by using the subtype selective antagonists nitrocaramiphen, AF-DX 116,  
4-DAMP and tropicamide. No significant changes in affinity of the chosen antagonists were 
observed in CHF rats compared to control group, and the receptor binding profile corresponded 
best to M2 mAChRs. However, other mAChR subtypes and changes in the mAChR profile in 
CHF rats may be present and can not be excluded because of the lack of highly selective 
antagonists for mAChR subtypes.
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2 INTRODUCTION 
 
Cardiac function is dynamically regulated by the autonomic nervous system, i.e. sympathetic 
which acts via the active molecules noradrenaline and adrenaline, and parasympathetic nervous 
system, which acts via acetylcholine. These active molecules, called neurohormones, are 
produced in the neuroendocrine system and mediate their effect by adrenaline and noradrenaline 
binding to adrenoceptors and acetylcholine binding to muscarinic acetylcholine receptors. The 
regulation can be influenced by physiological factors and diseased states like congestive heart 
failure, and the balance between normal control of the heart and deleterious dysregulation might 
be shifted. The aim of this thesis was to look for possible changes in the muscarinic acetylcholine 
receptors in congestive heart failure by receptor binding experiments. 
 
2.1 Congestive heart failure 
2.1.1 Classification and pathophysiology 
 
Congestive heart failure (CHF) has many definitions. One commonly used is a progressive 
pathophysiological state in which an abnormality of cardiac function is responsible for the failure 
of the heart to pump enough blood required by the metabolising tissues at normal chamber 
volumes and pressures (Remme and Swedberg, 2002). Patients with congestive heart failure have 
often symptoms of volume overload, like retention of fluid (congestion) in different parts of the 
body, such as legs, liver and lungs that cause shortness of breath and lung sound on the 
examination. Other symptoms may be related to inadequate tissue perfusion such as impaired 
exercise tolerance, fatigue and renal dysfunction. These symptoms will not be present in 
asymptomatic left ventricle dysfunction/heart failure when initial compensatory mechanisms are 
able to modulate left ventricle function to maintain the functional capacity.  
 
Currently, heart failure is defined by four stages A-D (Table 1) complementing the traditional 
New York Heart Association (NYHA) classification (Table 2) (Cowie et al., 1999;Hunt et al., 
2001), to recognise the initial risks and the progression of this syndrome. 
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Table 1: Heart failure is currently identified by four stages A-D according to the American College of  
Cardiology/American Heart Association guidelines.  
Stage A High risk of developing heart failure. No apparent structural abnormality 
of the heart. 
Stage B Structural abnormality of the heart but never had symptoms of heart 
failure. 
Stage C Structural abnormality of the heart. Current or previous symptoms of heart 
failure. 
Stage D  End stage symptoms of heart failure that are refractory to standard 
 treatment. 
 
   
Table 2: The NYHA classification of congestive heart failure 
Class I (Mild) No limitation of physical activity. Ordinary physical activity does not 
cause any symptoms like fatigue, palpitation or dyspnea (shortness of 
breath).  
Class II (Mild) Slight, mild limitation of activity. Comfortable at rest, but ordinary 
physical activity causes fatigue, palpitation or dyspnea. 
Class III (Moderate) Marked limitation of activity. Comfortable only at rest, and less than 
ordinary activity causes fatigue, palpitation or dyspnea. 
Class IV (Severe) Unable to carry out any physical activity without discomfort. Symptoms of 
cardiac insufficiency at rest.  
 
Congestive heart failure is a growing problem in the western countries. Approximately 2% of the 
population suffer from heart failure (Cowie et al., 1999) and the syndrome becomes more 
common with increasing age. It is estimated that approximately 10% of persons over 74 years 
have heart failure or have had heart failure for a short period as a consequence of other cardiac 
diseases (Madsen, 1994;Gullestad and Madsen, 2004). Approximately one third of the patients 
with congestive heart failure are hospitalized during one year (Gullestad and Madsen, 2004) and 
the treatment of congestive heart failure is associated with high costs for the society (Haldeman et 
al., 1999). Severe heart failure is a syndrome with a prognosis worse than many cancers. Half of 
the patients with chronic heart failure die within four years, and severe heart failure (NYHA class 
IV) has a one-year mortality of almost 50% (Cleland et al., 1999). The cause of death seems to be 
either development of a more severe heart failure or arrhythmias (Gullestad and Madsen, 2004). 
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In the MERIT-HF study 91% of the deaths were caused by cardiovascular events (Hjalmarson et 
al., 1999). Despite growing understanding of the regulation of cardiac function, more needs to be 
known about the basal mechanisms to develop new potent therapeutic strategies to be able to 
improve the prognosis for heart failure patients. 
 
There are several causes of congestive heart failure, and if possible, preventing or treating the 
primary defect such as hypertension, is desirable. CHF can be caused by for instance ischemic 
heart disease, hypertension, arrhythmias, valve abnormalities and pericardial diseases. To 
maintain arterial pressure and perfusion of vital organs, different compensatory mechanisms are 
initiated which are the same as those being activated to increase cardiac output in daily situations. 
The most important responses are the Frank-Starling mechanism, myocardial hypertrophy, 
ventricular dilation and activation of neurohumoral systems, like release of noradrenaline, 
activation of the renin-angiotensin-aldosterone system and release of atrial natriuretic peptide 
(ANP). These mechanisms, some of them also called remodelling, can initially be adaptive and 
keep the blood supply sufficient for a short period to adapt to new requirements. However, they 
will over time become maladaptive, for instance during continued activation of neurohormonal 
responses in diseased states and initiate an unphysiological growth process by growth of the cells 
in length (i.e eccentric hypertrophy) that is accompanied with increased mechanical stress, 
increased protein synthesis, altered expression of genes regulating contractility, expression of 
fatal gene products and loss of cardiomyocytes by apoptosis or necrosis as some important 
factors (figure 1). 
 
Overactivation of the adrenergic drive may be a result of both increased release and decreased 
reuptake of neurotransmitter, resulting in a constant exposure of the heart to levels of 
noradrenaline that are probably toxic to the heart (Braunwald and Bristow, 2000). Other changes 
in the adrenergic system are further described in part 2.3.1 “Adrenoceptors”. In heart failure the 
level of circulating and tissue concentration of angiotensin II is elevated causing increased 
ventricular afterload, myocyte hypertrophy, apoptosis, interstitial fibrosis, cardiac and vascular 
remodelling and increased secretion of aldosterone (Braunwald and Bristow, 2000). Activation of 
natriuretic peptides, endothelin and vasopressin may also play a critical role in the pathological 
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remodelling and thereby in the pathogenesis and progression of CHF (figure 1).  
 
Figure 1: A schematic presentation of the pathogenesis of congestive heart failure. (After Textbook of 
Therapeutics: Drug and Disease Management  (2000)). 
 
2.1.2 Treatment of heart failure 
 
The approaches to therapy are intended to treat the underlying causes, remove contributing 
factors that can worsen heart failure and treat the heart failure itself. When it comes to therapy, in 
the last few decades, there has been a change in the approach of therapy in heart failure. Until the 
1980’s, the attention was brought to altered hemodynamics as a cause of heart failure, and this 
model naturally directed the treatment. Positive inotropic drugs and vasodilators were the drugs 
of choice and the effect was characterised as changes in the hemodynamic factors. Since the 
1980’s the neurohormonal model is the main model because of the growing knowledge of the 
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importance of neuroendocrine systems in the development and the progression of heart failure. 
The drugs are designed to reduce the effect of the neurohormonal compensatory mechanisms that 
are initiated in heart failure. The treatment is currently based on β-blockers and ACE-inhibitors 
because of their beneficial effect on morbidity and mortality. The effect of β-blockers was not 
expected from a hemodynamic point of view because β-blockers reduce the inotropic effect. It 
was commonly thought that in heart failure it was necessary with increased adrenergic 
stimulation of the heart for adequate blood supply to the body.  
 
Usually combinations of drugs with different targets are used for treatment of heart failure, 
depending on other additional diseases, underlying causes and types of CHF. Other examples of 
drugs used in drug therapy of heart failure are angiotensin II receptor antagonists, diuretics, 
aldosterone antagonists, heart glycosides, combined β- and α1-AR antagonists and long acting 
nitrates.  
 
2.2 G protein coupled receptors 
2.2.1 Structure and classification of G protein coupled receptors 
 
The most common type of receptors in the heart mediating the signals from neurohormonal 
stimulation is the guanine nucleotide binding protein (G protein) coupled receptors (GPCR). The 
most important examples in the heart are the adrenoceptors and the muscarinic acetylcholine 
receptors because they have an important function in the homeostatic regulation of the heart, but 
angiotensin, endothelin and the serotonergic receptors are also examples of GPCRs that 
participate in the homeostatic regulation. In addition several other kinds of receptors belong to 
the GPCRs, such as dopamine receptors, opiate receptors, purine receptors and receptors for 
many peptides (Rang et al., 1999). A wide variety of physiological functions are regulated by 
GPCRs, and therefore, GPCRs are a major target for drug development. It was estimated in 2002 
that 30% of the pharmaceutical drugs were ligands for GPCRs (Hopkins and Groom, 2002). 
Knowledge about the mechanisms of signalling of GPCRs is essential for understanding of the 
development of heart failure and further drug discovery. 
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GPCRs are divided in three main families according to their amino-acid sequence, where 
receptors from different families share essentially no sequence similarity (Bockaert and Pin, 
1999). Family 1 contains most GPCRs and includes receptors for small ligands like 
catecholamines (1a), peptides (1b) and glycoprotein hormones (1c). Family 2 includes receptors 
for high molecular weight hormones such as glucagon. Family 3 contains receptors such as 
glutamate receptors, Ca2+ sensing receptor and gamma hydroxyl butyric acid-B (GABAB) 
receptors, which have in common a very large extracellular domain. In addition, two other 
families have been described. Family 4 comprises pheromone receptors associated with Gi and 
family 5 includes receptors involved in embryonic development, cell polarity and segmentation. 
Finally cAMP receptors have been classified in one family since they have only been found in 
D.discoideum. 
 
All GPCRs are cell surface receptors and have a common central core domain consisting of seven 
transmembrane α-helices connected by three intracellular and three extracellular loops. Most of 
the GPCRs also have two cysteine residues which form a disulfide bond. This may be important 
in packing and stabilising the conformations of the GPCRs. The intracellular carboxyl(C)-
terminal domain, extracellular amino(N)-terminal domain and the intracellular loops differ in 
length and function which provide specific properties to the various receptor proteins (Bockaert 
and Pin, 1999).  
 
GPCRs can recognise a diverse group of agonists, for instance light, Ca2+, odorants, small 
molecules including amino-acid residues, nucleotides, peptides and proteins (Bockaert and Pin, 
1999). The interaction between the agonist and the receptor may stabilise a change in the 
conformation of the core domain, generally in the second and third intracellular loop, constituting 
one of the key sites for G protein recognition and activation.  
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2.2.2 Heterotrimeric G proteins 
 
G proteins are the signal mediators between the cell-surface receptor and the intracellular 
effectors. These proteins interact mostly with the third intracellular loop of the GPCRs. Activated 
G proteins mediate their function through enzymes and ion channels. Their interaction with the 
receptor may change in diseased states like heart failure. 
 
G proteins are heterotrimeric and consist of α, β and γ subunits (Rang et al., 1999). In the non-
activated state, the α-subunit interacts with guanosine diphosphate (GDP) and is tightly 
associated with the βγ-complex. Upon activation of GPCRs by agonists, the α-subunit exchanges 
the bound GDP with GTP, resulting in the dissociation of the G protein from the GPCR and the 
dissociation of the α-subunit from the βγ-complex. The β- and the γ-subunits remain associated as 
a complex, anchored to the membrane through a fatty acid chain attached to an amino acid. The 
GTP-bound α-subunit and the βγ-complex can both regulate activities of different intracellular 
pathways, dependent on the class of G protein(s) activated (figure 2). 
 
There is a variety of G proteins because of all the possible combinations of different subtypes of 
α-, β- and γ-subunits. At least 18 different subtypes of α-subunits have been identified (Wong, 
2003). They can be divided into four subfamilies: 1) the Gs subfamily that stimulates adenylyl 
cyclase (AC), 2) the Gi/o subfamily that inhibits AC and regulates ion channels, 3) the Gq/11 
subfamily that activates phospholipase C β and 4) the G12/13 subfamily where the knowledge is 
limited about its effects, but the G12/13 subfamily seems to activate the Na+/H+ exchanger (Wong, 
2003). Dependent on the subtype(s) of the G protein α-subunit that a GPCR interacts with, a 
single or a combination of effectors can be activated (Wong, 2003). A further description of the 
subfamilies is given in table 3 below. The great variety of G proteins which is also caused by the 
five subtypes of β-subunits and eleven subtypes of γ-subunits identified, gives the opportunity for 
a variety of combinations of G proteins and hence a diversity of activated intracellular pathways 
by GPCRs (Wong, 2003). 
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Table 3: Subfamilies of G proteins and examples of receptors, intracellular signalling and effects induced 
upon activation of GPCRs in the heart. AC, adenylyl cyclase; PLC-β, phospholipase C-β; IP3, inositol 1,4,5-
trisphosphate and DAG, diacylglycerol. 
Example of 
receptors 
G 
proteins 
Effectors Second 
messengers 
Effects 
β1, β2  Gs AC 
Ion channels 
↑cAMP 
Ion flux 
Positive inotropic and chronotropic 
effect 
Increased metabolism 
M2, M4 Gi AC 
K+ channel 
Ca2+ channel 
↓ cAMP 
K+ efflux 
Negative inotropic and chronotropic 
effect 
α1A, α1B, α1D 
M1, M3, M5 
Gq PLC-β IP3, DAG, 
Ca2+ 
Positive inotropic effect 
Unknown G12/13 e.g 
Na+/Cl- 
exchanger 
e.g 
Na+/Cl- 
exchange 
Limited knowledge about the 
distribution and the effects of G12/13 
in the heart 
Several βγ e.g 
AC 
K+ channels 
Receptor 
kinases 
e.g 
↓/↑ cAMP 
K+ efflux 
e.g 
Altered inotropy 
 
Receptor desensitisation 
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Figure 2: Seven transmembrane spanning (I-VII) G protein coupled receptor with an interacting G protein 
(α/βγ). Activation of the receptor catalyses the replacement of GDP with GTP on Gα, followed by dissociation of the 
Gα and Gβγ subunits. Both subunits can interact with various proteins and initiate further signalling inside the cell. 
(After Qvigstad (2004)). 
 
The activation of G proteins is terminated through the GTPase activity of the α-subunit, which 
hydrolyses GTP to GDP. This reaction causes the GDP bound α-subunit to reassociate with the 
βγ-complex, which allows several agonist-receptor complexes to activate several G proteins in 
turn and repetitive receptor-G protein coupling. 
 
2.3 G protein coupled receptors involved in heart failure 
 
The autonomic nervous system is important in the regulation of the heart and a further 
presentation of the functional receptors of the sympathetic and the parasympathetic nervous 
system is given below. 
2.3.1 Adrenoceptors 
 
Myocardial adrenoceptors belong to the family of G protein coupled receptors and are divided 
into three receptor types: α1-, α2- and β-adrenoceptors with further subtypes (figure 3). The 
endogenous agonists for these receptors are noradrenaline and dopamine released from 
sympathetic nerve endings and adrenaline released from the adrenal medulla.  
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Figure 3: Adrenoceptor subtypes. (After Brodde & Michel (1999)). A putative β4-AR has been discussed, but is 
now thought to represent a state of β1-AR (Kaumann et al., 2001). 
 
Three subtypes of α1-adrenoceptors (α1-AR) have been identified through molecular cloning and 
pharmacologically (α1A, α1B and α1D) (Brodde et al., 2001). In the rat heart all three subtypes have 
been identified at the mRNA level and α1B-AR mRNA accounts for 50% of the total α1-AR 
mRNA in the heart. Only α1A-AR and α1B –AR, however, seem to be expressed at the protein 
level in a ratio of 20% to 80% in rat ventricles (Michel et al., 1994). α2-adrenoceptors (α2-ARs) 
are present in nerve terminals in the heart, but the presence of α2-ARs postsynaptic on the 
cardiomyocytes is still a matter of debate. 
 
α1-ARs are assumed to couple primarily via a pertussis toxin (PTX)-insensitive G protein (Gq/11) 
to phospholipase C/inositol trisphosphate/diacylglycerol (PLC/IP3/DAG) system (Brodde et al., 
2001). Activation of α1-ARs mediates a slowly developing increased force of contraction 
(positive inotropic effect) which has been demonstrated in several species including human and 
rat, but the mechanisms involved are still a matter of debate. The increased IP3-formation 
following α1-AR stimulation, might mediate the release of Ca2+ from intracellular stores which 
could be involved. In addition, it has been found that α1-AR stimulation increases the Ca2+-
sensitivity of myofilaments (Brodde et al., 2001). Stimulation of α1-ARs can also induce cardiac 
hypertrophy in rat, but it is unknown whether this phenomenon is present in the human heart 
(Brodde et al., 2001). These effects suggest an important role in regulation of cardiac 
homeostasis, in rest, exercise and in diseased states. Little is known about the regulation of α1-
ARs in heart failure, but it has been speculated that α1-ARs may function as a compensatory 
mechanism in the heart to maintain inotropy when the β-ARs are down regulated and uncoupled 
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(Sjaastad et al., 2003). Because of the effects of α1-AR stimulation and in agreement with the 
neurohormonal model, antagonism of α1-AR may still have a beneficial effect in long term 
treatment of heart failure in combination with β-blockers, despite the observed higher incidence 
of stroke and combined cardiovascular disease in treatment with doxazosin, an α1-AR antagonist, 
alone compared to treatment with diuretics (Davis et al., 2000). 
 
In the heart, three different β-adrenoceptor subtypes have been identified through cloning and 
pharmacologically and they are designed β1, β2 and β3 (figure 3). The existence of a putative β4-
AR has been discussed (Brodde and Michel, 1999), but is now thought to represent a state of β1-
AR (Kaumann et al., 2001). The β1-AR is the predominant β-AR in mammalian heart and 
comprises about 70-80% of the total receptor number in normal ventricles. 
 
Both β1-ARs and β2-ARs couple to Gs which stimulates AC and increases the cytosolic level of 
the second messenger cAMP. This in turn activates the cAMP dependent protein kinase A 
(PKA). PKA mediates phosphorylation of a variety of cellular effector proteins involved in the 
inotropic, lusitropic (cardiac relaxation), chronotropic (heart rate), growth promoting and 
cytotoxic effects. In addition, there is some evidence for β2-AR coupling to Gi in mammalian 
species (Kilts et al., 2000;Xiao et al., 2004). 
 
It is generally accepted that in patients with chronic heart failure, there is a decrease in cardiac β1-
AR both at the mRNA- and protein-level and an uncoupling of cardiac β2-AR. There seems to be 
no change in the amount and functional activity of cardiac Gs, but an upregulation of the activity 
and amount of cardiac Gi (shown in most studies). Another change observed is an upregulation of 
mRNA levels and phosphorylation activity of cardiac β-AR kinase. There seems to be no change 
in the activity of the catalytic unit of adenylyl cyclase and PKA (Giessler et al., 1999). Chronic 
stimulation of β-ARs has also seemed to induce expression of the cytokines tumour necrosis 
factor-α, interleukin-1 and interleukin-6 which may alter cardiac contraction, promote chamber 
enlargement, and thus play a significant role in the development of a dilated cardiomyopathy 
(Braunwald and Bristow, 2000). 
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2.3.2 Muscarinic acetylcholine receptors (mAChRs)  
 
Muscarinic acetylcholine receptors mediate the parasympathetic control of the heart, and these 
receptors cause alternations in the inotropic and chronotropic response to catecholamines. Five 
different mAChRs have been cloned and identified pharmacologically so far, and they are 
designed M1, M2, M3, M4 and M5 (Caulfield and Birdsall, 1998) (figure 4). The odd numbered 
subtypes of the mAChRs (M1, M3 and M5) are coupled preferentially via Gq/11 to PLC and 
thereby formation of inositol phosphates, such as IP3 and DAG. The even-numbered subtypes 
(M2 and M4) are coupled via Gi and hence to inhibition of adenylyl cyclase and thereby reduced 
intracellular cAMP (Caulfield and Birdsall, 1998). 
 
 
 
Figure 4: Muscarinic acetylcholine receptor subtypes.  (After Brodde & Michel (1999)). 
 
It is a general agreement that the main subtype of mAChRs in the heart of various mammalian 
species is M2 mAChR (Brodde et al., 2001;Dhein et al., 2001). Stimulation of M2 mAChRs 
causes negative inotropic and chronotropic effects in the heart. In atria, a direct negative 
chronotropic effect is mediated by stimulation of M2 mAChRs and, in isolated tissue, inotropic 
effects. In the ventricles, however, the negative inotropic effect is only present when the basal 
force of contraction has been enhanced by cAMP-elevating agents, such as β-AR agonists, 
forskolin or phosphodiesterase inhibitors (Brodde and Michel, 1999). In addition to the common 
mechanism of inhibition of adenylyl cyclase, in atria acetylcholine opens potassium channels 
(IK.Ach) by the G-protein βγ-subunit causing a reduction in the force of contraction. 
 
Since M2 mAChRs were long believed to be the only functional mAChRs in the heart, this tissue 
was commonly used as a model illustrating the exclusive presence of M2 mAChRs. This concept 
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that the heart possesses only M2 mAChRs has been challenged in the last decade. Many 
physiological responses to mAChR stimulation cannot be explained on the basis of a single M2 
mAChR subtype in the heart. Accumulating evidence suggests the existence of mAChR subtypes 
other than M2 mAChR in cardiac tissues of chickens, rats, guinea pigs, rabbits, dogs and humans 
with large variations of subtype expression among species (Dhein et al., 2001). Functional  
M3 mAChRs in rat ventricular cardiomyocytes and human atria have recently been demonstrated 
(Willmy-Matthes et al., 2003;Ponicke et al., 2003). The presence of M1 mAChRs was also 
demonstrated by RT-PCR detection both in guinea-pig and rat (Gallo et al., 1993;Sharma et al., 
1997) and functional identification in rat (Sharma et al., 1996). Quantification of the different 
mAChR subtypes at mRNA level by quantitative polymerase chain reaction (PCR) in normal rat 
heart showed that the M2 mAChR mRNA represented more than 90% of total mAChR mRNA, 
while the concentrations of M1, M3, M4 and M5 mAChRs mRNA were less than 1%, 3%, 1% and 
5% respectively (Krejci and Tucek, 2002). 
 
There seem to be regional differences in the distribution of mAChRs in the heart. The 
parasympathetic innervation is denser in the sinoatrial and the atrioventricular nodes than in the 
left ventricle of the human heart (Kent et al., 1974;Loffelholz and Pappano, 1985). The number 
of M2 mAChRs is up to 2.5-fold higher in the atria compared to the ventricles (Brodde et al., 
2001). The distribution and functional responsiveness to M2 mAChRs have in general been 
reported not to be altered in chronic heart failure (Brodde et al., 2001;Dhein et al., 2001). Less is 
known about the other mAChRs in CHF. However, Tveit found an increase in ventricular M3 
mAChR and M4 mAChR at mRNA level in CHF rats compared to Sham rats (Tveit, 2003). 
 
2.4 Background for the present study 
 
Unpublished data from Hussain et al. showed a novel effect of mAChR stimulation in papillary 
muscles from rats with CHF. The same animal model of CHF was used as described in part 3.1.1 
“Induction of myocardial infarction” in this thesis. Stimulation of papillary muscles with a β-AR 
agonist, isoproterenol, causes a positive inotropic response. This is a Gs mediated response 
through stimulation of AC and increase of cAMP resulting in an increase in the force of 
contraction. When this response was antagonised by a non-selective mAChR agonist, carbachol 
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(CCh), CCh did not only inhibit the β-AR stimulated inotropic effect, but it also elicited a 
positive inotropic response itself in the papillary muscles derived from rats with CHF (Hussain et 
al. unpublished). This inotropic response to CCh was more than 60% of the inotropic response 
mediated by the β-agonist, isoproterenol, in rats with CHF. This phenomenon seemed to be 
absent in papillary muscles derived from rats that had infarctions and no increase in left 
ventricular enddiastolic pressure (LVEDP) (Hussain et al. unpublished). This result may indicate 
that the response observed is a phenomenon in rats with CHF related to an increase in the 
LVEDP and not to the induced infarction and necrosis. To determine which mAChR subtype 
which mediates this CCh induced inotropic response, different selective antagonists for the 
different mAChR subtypes were used to try to antagonise this effect in dose-response curves. The 
chosen antagonists were nitrocaramiphen, an M1 mAChR selective antagonist, AF-DX 116, an 
M2 mAChR selective antagonist and 4-DAMP, an M3 mAChR selective antagonist (see part 3.2.1 
“Ligands and experimental conditions for the receptor binding assay” for more information on 
the selective antagonists). Only the selective antagonist for M2 mAChRs, AF-DX 116, made a 
significant shift in the dose-response curve to a higher concentration of agonist which indicated 
that the CCh induced inotropic response was most likely mediated through M2 mAChRs. This is 
in contrast to the well accepted hypothesis that M2 mAChRs couple to Gi protein in normal heart, 
inhibiting AC and the formation of cAMP. 
 
One of the hypotheses concerning the CCh induced positive inotropic response in the functional 
study described above is that the response is due to pathophysiological changes that occur in 
CHF. One suggestion is that the M2 mAChRs may be coupled to two different pathways in CHF, 
one Gi protein mediated pathway by inhibiting AC and the formation of cAMP as described 
above one Gq protein mediated pathway by activating PLC which catalyses the formation of IP3 
and DAG. This could be present in the M2 mAChRs as a change in affinity in CHF compared to 
normal hearts. However, other pathways cannot be excluded. One reason to suggest that 
 M2 mAChRs may be coupled to Gq protein is that the contraction-relaxation cycle of the CCh 
induced positive inotropic response resembles the contraction-relaxation cycle derived from α1-
AR- and endothelin-stimulated papillary muscles. Both the α1-ARs and the endothelin receptors 
are Gq coupled receptors.  
 
   
 21
2.5 Aims of the present study 
 
The aim of this study was to look for possible changes in muscarinic acetylcholine receptors in 
CHF compared to normal cardiac ventricular membranes by receptor binding experiments, using 
6-week post myocardial infarction CHF rats as a model system.  
 
More specifically it was of interest to: 
 
1. Characterise the density of muscarinic acetylcholine receptors and their affinity for the 
radioligand used, [3H]QNB, in cardiac ventricular membranes from CHF, sham operated 
and normal rats. 
 
2. Study the interaction between muscarinic acetylcholine receptors and G proteins by 
examining agonist high-affinity binding and its regulation by guanine nucleotides in CHF, 
sham operated and normal rats. 
 
3. Characterise the profile of muscarinic acetylcholine receptor subtypes in cardiac 
ventricular membranes from CHF, sham operated and normal rats by studying the binding 
affinity profile of several selective antagonists for the different mAChR subtypes. 
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3 METHODS 
 
A general presentation of the methods is given in this chapter (part 3 “Methods”) while the 
details for the practical approach of this study, is presented in the protocols in the appendix (part 
8.2 “Protocols”). 
 
3.1 Heart tissue – the CHF model 
3.1.1 Induction of myocardial infarction 
 
Animals were cared for according to the Norwegian Animal Welfare Act and two rats were kept 
in each cage and housed in a temperature regulated room on a 12:12-h day/night cycle. The 
animals were given access to food and water ad libitum. An extensive infarction was induced by 
proximal ligation of the left coronary artery in approximately 200 g male Wistar rats under 
anaesthesia (68% N2O, 29% O2 and 2-3% isofluran (Abbot Park, Illinois, USA)). 
 
Six weeks post infarction the rats were anaesthetised and ventilated as described above and 
catheterised for LVEDP measurements. CHF rats with a LVEDP ≥ 15 mmHg and a significantly 
increased heart and lung weight were included in the study (Sjaastad et al., 2003). 
 
Sham rats were operated in parallel and left ventricles from these rats were used as a control 
group in this study. They went through the same surgical procedure (a thoracotomy), but the 
coronary artery was not ligated. 
 
Left ventricles from operated rats were all obtained from Institute for Experimental Medical 
Research, Ullevål University Hospital (Research group of professor Ole M. Sejersted). 
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3.1.2 Tissue sampling 
 
During anaesthesia, the chest was opened in the rats and the heart removed. The ventricular 
tissue, separated in left and right ventricles, was immediately frozen in liquid nitrogen and kept 
frozen at –70 °C. 
 
The normal rats, non-operated, obtained from Centre for Comparative Medicine, Rikshospitalet 
University Hospital, were anaesthetised with ether and killed. The chest was opened and the heart 
removed. The heart was perfused with 0.9% sodium chloride (NaCl). The heart atria were 
removed. The ventricles were immediately frozen by using the freeze-clamp method and the 
remaining atria tissue was removed with forceps. The heart tissue was kept frozen at -70 °C until 
smashing. 
 
The heart was powdered in a mortar cooled in liquid nitrogen. The cardiac ventricular tissue was 
stored at – 70 °C until use. 
 
3.1.3 Preparation of cardiac ventricular membranes 
 
The membrane preparation was made as previously described by others (Mügge et al., 1985) with 
modifications. The cardiac ventricular membranes had to be disrupted to increase access of the 
radioligand to the receptor population. During the tissue homogenisation, high levels of proteases 
can become available for receptor degradation. To prevent activation of proteolysis, denaturation 
of the receptors and loss of receptor binding sites, the tissue was kept frozen until it was used and 
kept cold during the whole preparation procedure by leaving all the equipment on ice while 
working. In addition cold solutions were used. Further addition of protease inhibitors may also be 
required to preserve the receptors. Ethylenedinitrilo tetraacetic acid (EDTA), a divalent cation 
chelating salt, was added to the tris, magnesium chloride and EDTA (TME) buffer in addition to 
phenylmethanesulfonyl fluorid (PMSF), an inhibitor of trypsin-like proteases and phenantroline, 
a metalloprotease inhibitor, which chelates iron, zinc and other divalent metals. PMSF and 
phenantroline were chosen according to other receptor binding studies in heart tissue performed 
by Jensen et al. and Dunlap et al.(1995;2003).  
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Myofilaments are present in the cardiac ventricular tissue. These large proteins can in receptor 
binding assays plug the glassfiber filters when filtration is the method of choice for separation of 
the receptor-radioligand complexes from unbound radioligand. To prevent plugging of the filters 
in this study, potassium chloride (KCl) at a final concentration of 0.5 mol/L was added initially to 
the homogenous membrane preparation. KCl was allowed to solubilise the myofilaments for 10 
minutes while the membrane preparation was kept cold on ice before the washing of the 
membranes started. 
 
Endogenous ligands for mAChR, such as acetylcholine, can interfere with the receptor binding. 
Therefore, it is necessary with a series of washing steps to remove the endogenous ligands. 
Especially for this study, it was important with several washing steps because of the competition 
experiments with carbachol in the absence and the presence of GTP. GTP is present in relatively 
high concentration in the heart tissue. If all the endogenous GTP had not been completely 
removed from the tissue during the washing procedure, this would have caused a shift in the 
calculated pKi values from the displacement of [3H]QNB by carbachol in the absence of added 
GTP. 
 
Each membrane preparation was made from ventricular tissue from one heart. The membrane 
preparation was used fresh to avoid molecular changes by freezing.  
 
3.2 Receptor binding assay 
3.2.1 Ligands and experimental conditions for the receptor binding assay 
 
The selected radioligand in this study was 1-quinacliinyl[phenyl-43H] benzilate ([3H]QNB); 
specific activity 42 Ci/mmol, which is a non-selective antagonist for mAChRs that binds almost 
equally to all mAChR subtypes (Myslivecek and Trojan, 2003b) (figure 5). This compound has 
traditionally been used as ligand to label mAChRs at least from 1974 (Yamamura and Snyder, 
1974). Because of the radioligand’s physical-chemical properties, [3H]QNB provides a simple, 
sensitive, specific assay for the mAChRs (Snyder et al., 1975). 
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Figure 5: Structural formula: 1-quinacliinyl[phenyl-43H] benzilate, [3H]QNB. The bold hydrogen atoms (H) 
represent the 3H in the structural formula. 
 
The binding experiments were performed by incubation of the cardiac ventricular membranes 
with the reagents for 120 minutes according to Myslivecek (2003a), except for the experiments to 
study if steady state was reached. However, the temperature was chosen to 24 °C to slow the 
reaction of proteases and to get an optimal receptor-G protein coupling, which is affected by a 
number of conditions and agents, such as pH, protein modification, proteases, ions and volatile 
anaesthetics (Aronstam and Narayanan, 1988). Aronstam and Narayanan also showed in 1988 
that the guanine nucleotide sensitivity of agonist binding to mAChRs in rat atrium, was affected 
by the temperature. The guanine nucleotide effect was more expressed from 15 to 20°C 
(Aronstam and Narayanan, 1988). To avoid temperature variation, all the experiments were 
performed at 24° in a waterbath. 
 
The incubation time must be sufficient for the interaction between the receptor and the 
radioligand to reach equilibrium as described in part 3.4.1 “Fundamentals of radioligand binding 
assay” and 3.4.2 “Saturation binding experiments”. To make sure equilibrium was obtained, 
saturation binding experiments with three critical concentrations of [3H]QNB were incubated for 
90, 120 and 150 minutes. Ventricular membranes from normal, Sham and CHF rats were used. 
 
In all the binding experiments, the total binding was referred to as the amount of radioligand 
bound in the absence of a competing ligand for mAChRs. The binding in the presence of the 
competing ligand is referred to as non-specific binding, and the difference between the two is 
referred to as specific binding. In this study atropine, a non-selective antagonist, was used as 
competing ligand at a final concentration of 1 µmol/L as also previously published by others for 
instance Oki et al. (2001). Another unlabelled ligand than QNB itself was used to define the 
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specific binding to reduce the probability of including binding sites other than the mAChRs in the 
specific binding.  
 
In addition to changes in receptor density and affinity studied in saturation binding experiments, 
changes in postreceptor mechanisms such as coupling to G proteins may underlie functional 
alterations in mAChRs transmission in CHF. This can be studied by examining agonist high-
affinity binding and its regulation by guanine nucleotides. In this study, displacement of the 
chosen radioligand by carbachol, a non-selective agonist of mAChRs, was performed in the 
absence and the presence of GTP (for structural formulas see figure 6). The concentration of GTP 
used in the study was 100 µmol/L. Some additional displacement experiments were also 
performed with the non-hydrolysable analogue of GTP, guanosine 5'-[β,γ-imido]triphosphate 
(Gpp(NH)p) in the same concentration as GTP. 
 
  
  
Figure 6: Structural formula: Guanosine 5'-triphosphate sodium salt (GTP) and carbachol 
   
Development of selective antagonists for the mAChR subtypes has made it possible to 
pharmacologically discriminate between different mAChRs and characterise the receptor subtype 
profile. Several compounds are available, which show reasonable selectivity towards different 
mAChR subtypes. The selective antagonists in this study were the same as in the functional study 
for M1, M2 and M3 mAChRs (Hussain et al. unpublished) and no second choice was done. In 
addition tropicamide was chosen as antagonist for M4 mAChRs according to the published data 
for its affinity to M4 mAChRs (table 4). 
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The antagonist for M1 mAChRs used in this study was 2-Diethylaminoethyl 1-(4-
nitrophenyl)cyclopentanecarboxylate hydrochloride, nitrocaramiphen (figure 7). 
 
 
Figure 7: Structural formula: Nitrocaramiphen  
 
The antagonist for M2 mAChRs used in this study was 11-[[2-[(Diethylamino)methyl]-1-
piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one, with the 
abbreviation AF-DX 116 (figure 8). 
 
Figure 8: Structural formula: AF-DX 116  
The selective antagonist chosen for M3 mAChRs was 1,1-Dimethyl-4-
diphenylacetoxypiperidinium iodide, with abbreviation 4-DAMP (figure 9). 
 
Figure 9: Structural formula: 4-DAMP 
An antagonist with high affinity for M4 mAChRs was N-Ethyl-3-hydroxy-2-phenyl-N-
(pyridinylmethyl)propanamide, with abbreviation tropicamide (figure 10). 
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Figure 10: Structural formula: Tropicamide 
There were no selective antagonists available with preferential affinity towards M5 mAChRs 
(Wang et al., 2004), and therefore, no affinity profile was obtained in this study for M5 mAChRs.  
Already published dissociation constants, Ki, for the selective antagonists used in the study and 
atropine are presented in table 4. 
Table 4: Dissociation constants, Ki, for the selective antagonists (nitrocaramiphen, AF-DX 116, 4-DAMP and 
tropicamide) and atropine (Caulfield, 1993;Hudkins et al., 1993;Eglen and Watson, 1996;Dhein et al., 
2001;Wang et al., 2004). All the values are shown as pKi (-log Ki). F, data from functional studies; C, data from 
studies on cloned receptors; B, data from radioligand-binding displacement studies.  
 M1 mAChR M2 mAChR M3 mAChR M4 mAChR M5 mAChR 
Atropine 9.0-9.7 9.0-9.3 8.9-9.8 9.1-9.6 8.9-9.7 
Nitrocaramiphen B: 8.25 B: 6.4 B: 7.24 - - 
AF-DX 116 B/C: 6.4-6.7 
F: 6.9 
7.1-7.2 B: 5.9 
F: 6.6 
B/C: 6.6 
F: 7 
6.6 
4-DAMP 8.9-9.2 
C: 9.2 
8-8.4 
C: 8.4 
8.9-9.3 
C: 9.3 
B/C: 8.9 
F: 9.4 
C: 9 
Tropicamide 7.2 7.3 7.4 7.8 - 
 
 
 
 
 
 
   
 29
3.2.2 Separation of receptor-radioligand complex from the unbound 
radioligand – non-specific binding 
 
The separation of the receptor-radioligand complex from the unbound radioligand, can be 
performed by both centrifugation and filtration. Filtration was chosen in this study because it is a 
more efficient method, requiring less handling of the samples. The termination of the reactions 
and the washing can be done much faster with filtration compared to centrifugation. Filtration is 
often the method of choice because the non-specific binding is usually lower. The high affinity of 
[3H]QNB for the mAChRs (see part 4.2.2 “Binding properties of [3H]QNB and muscarinic 
acetylcholine receptor density in rat ventricular membranes”) combined with cold washing buffer 
will minimize the dissociation of the receptor-radioligand complex during the washing of the 
filters. 
 
The radioligand, [3H]QNB, may also interact with the glassfiber filters. This binding was not 
displaceable in the presence of 1 µmol/L atropine (data not shown). Because of this, the binding 
of [3H]QNB to the filter was a part of the non-specific binding. 
 
3.3 Protein quantification 
 
To calculate the results from the study, it is commonly accepted to relate the amount of 
radioactive binding to the total amount of protein present. To determine the amount of protein in 
each sample, BC (bicinchoninic acid) Assay: Protein Quantitation Kit from Uptima and a Perkin 
Elmer HTS 7000 Bio Assay Reader was used. Proteins reduce Cu2+ in alkaline solutions to Cu+. 
Two molecules bicinchoninic acid (BCA) react with each Cu+ resulting in a red water soluble 
complex with an absorption maximum of 562 nm. Absorbance is proportional to the total protein 
concentration between 5-20 µg/mL to 1-2 mg/mL, which allows spectrophotometric 
quantification of protein in aqueous solutions. 
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3.4 Receptor binding assays – analysis and calculations 
3.4.1 Fundamentals of receptor binding assays 
 
Receptor binding studies used to determine the affinity (1/Kd) of different substances for a given 
receptor and to determine the density of receptor in different tissues or samples are called 
saturation binding experiments. The method can also be used to measure the affinity (1/Ki) of 
unlabelled ligands for given receptors, called competition binding experiments. By using 
selective ligands, this method can be used to differentiate between receptor subtypes and 
characterise the receptor subtype profile. 
 
The following criteria must be met to define a binding site a receptor and to be able to validate 
the binding assay (McKinney, 1998).  
 
For binding sites to represent functional receptors, the binding needs to be specific which means 
it has to be displaceable by relevant unlabelled ligands in a relative low concentration range. All 
ligands, both agonists and antagonists, also have to inhibit the binding of the radioligand to the 
similar level of non-displaceable binding. The specific binding also needs to be characterised by 
the following criteria: 
 
o The binding should be saturable, indicating a finite number of binding sites. 
o The binding affinity, represented by the equilibrium dissociation constant (Kd), should be 
consistent with values determined for physiological receptors. 
o The binding should be reversible, consistent with the physiological mechanism for 
dissociation of an endogenous ligand to a receptor. 
o The binding site must have a relatively high affinity for the available ligands and a low or 
no affinity for other substances. 
o The pharmacology of binding for both agonists and antagonists should be consistent with 
the pharmacology of the natural ligand in functional and whole-animal systems. 
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The binding of a radioactive ligand to a receptor is a bimolecular reaction according to the Law 
of Mass Action. A radioligand (L*) combines with a receptor (R) by diffusion and forms a 
complex (L*R) (McKinney, 1998): 
 
        k+1 
L* + R  ↔  L*R        Equation (1) 
        k-1 
 
The rate of the forward reaction is dependent on the concentration of L* and R and is given by 
the constant k+1, the association constant, which has the unit of (time-1 x concentration-1). 
 
Forward rate = k+1 x [L*] x [R]      Equation (2) 
 
The binding is reversible and the complex, L*R, starts to dissociate, dependent on the amount of 
the complex and the dissociation constant, k-1 which is expressed in units of time-1. 
 
Reverse rate = k-1 x [L*R]      Equation (3) 
 
At equilibrium, the rate of the association and the rate of the dissociation is equal and the amount 
of L*, R and L*R will be constant. The ratio of the rate constants (k-1/k+1) will be equal to the 
equilibrium dissociation constant, Kd. 
        
      k-1        [L*] x [R] 
Kd =   k+1  =       [L*R]       Equation (4) 
 
Kd is expressed in units of concentration, such as nmol/L, and represents the concentration of 
ligand required to occupy 50% of the receptor in the tissue and is an expression for the affinity of 
the ligand for the receptor. According to the equations given above, one fundamental requirement 
in equilibrium binding experiments, such as saturation- and competition binding experiments, is 
that the reactants are incubated for sufficient time to reach equilibrium. 
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3.4.2 Saturation binding experiments 
 
In a saturation binding experiment, increasing concentrations of the radioligand, [3H]QNB, is 
incubated with the receptors, producing increasing concentrations of receptor-radioligand 
complexes. The theoretical maximal amount of receptor-radioligand complexes is called Bmax, 
expressed as fmol/mg protein, and it represents the density of the mAChRs in the membrane 
preparation from the cardiac ventricles in this study. The results can be presented in a saturation 
plot, where the concentration of the radioligand bound to the receptor is presented as a hyperbola 
with the following equation: 
 
              
Bmax x [Free radioligand] 
[Bound radioligand] =
     Kd + [Free radioligand]    Equation (5) 
 
where the free concentration of the radioligand represents the concentration at the end of the 
incubation period. One practical criterion for this equation is that the receptor concentration has 
to be low enough for the free radioligand concentration at the end of the assay to be essentially 
equal to the concentration of ligand present at the beginning of the assay. If not, it is preferred to 
calculate the concentration of free radioligand at the end of the assay as the difference between 
the concentration of radioligand added and the concentration of radioligand bound, both non-
specific and total. 
 
The graphical method to precisely determine the Kd value and Bmax is the Scatchard (Rosenthal) 
plot (Scatchard, 1949;Rosenthal, 1967). The concentration of bound/free (B/F) radioligand is 
plotted vs. bound (B) radioligand. A homogenous non-cooperative population of receptors will 
give a straight line, where the slope of the plot represents the negative of the inverse of the 
equilibrium dissociation constant, Kd and the x-intercept represents the theoretical maximal 
amount of specific binding sites, Bmax. A non-linear Scatchard plot can be decomposed in two or 
more components, and may indicate multiple subtypes of receptors with different binding profile 
to the radioligand or cooperativities between receptors. A non-linear regression program in 
Microsoft Office Excel 2003 (by professor dr.med Finn Olav Levy, Department of 
Pharmacology, University of Oslo) was used to analyse the graphs as further described in part 
3.4.4 “Calculations and statistics”. 
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3.4.3 Competition binding experiments 
 
In a competition binding experiment, various concentrations of an unlabelled ligand compete 
with a fixed concentration of a radioligand, [3H]QNB in this study, for binding to the receptor 
sites. 
 
R + L* + I  ↔  RL* + RI       Equation (6) 
 
where I presents the unlabelled ligand. The concentration of unlabelled ligand that inhibits 50% 
of the binding of the radioligand, [3H]QNB, is called IC50. The equilibrium dissociation constant 
for the unlabelled ligand for the receptor is called Ki. IC50 is related to both the ratio between the 
concentration of the radioligand, [L], and the Kd value, and the Ki value. Therefore, the Ki value 
can be obtained by using the Cheng-Prusoff equation (Cheng and Prusoff, 1973). 
 
           IC50                
Ki =
 1 + ([L]/Kd)        Equation (7) 
 
Analyses of the competition curves were performed by computer assisted program, GraphPad 
Prism® version 4 (GraphPad Software, CA, USA) assuming the existence of both low affinity 
sites and for high affinity sites. All experimental data were thus analysed for one or two binding 
sites by statistical evaluation.   
 
3.4.4 Calculations and statistics 
 
The affinity and density of muscarinic acetylcholine receptors were analysed and calculated by a 
non-linear regression program in Microsoft Office Excel 2003 with the Solver add in using the 
equation (5) (by professor Finn Olav Levy, Department of Pharmacology, University of Oslo). 
The non-specific binding was assumed to be linear and analysed by linear regression. The 
concentration of free [3H]QNB was estimated as the difference between [3H]QNB added and 
[3H]QNB bound (non-specific and total). The specific binding data were fit to equation (5). 
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Scatchard plot as described in part 3.4.2 “Saturation binding experiments” was plotted for 
illustration. The displacement of [3H]QNB by carbachol, atropine and the selective antagonists 
for the mAChR subtypes was analysed by using GraphPad Prism® version 4 (GraphPad Software, 
CA, USA) as described in part 3.4.3 “Competition binding experiments”. The curves were 
constructed as percent of maximum specific binding of the radioligand, [3H]QNB, to the binding 
sites. 
 
Data are expressed as mean ± standard error of the mean (S.E.M) and the number of animals are 
expressed as n. Statistical significance was estimated by Student’s t-test for comparing one- or 
two- binding site model with the statistical analysis in GraphPad Prism® version 4 (GraphPad 
Software, CA, USA). It was tested if a two-site model was significantly better than a one-site 
model. Significance level, α, was set to 0.05. A P value of ≤ 0.05 was considered statistically 
significant. Statistical analysis of the results was also performed by using Student’s t-test with the 
same statistical parameters. When appropriate, Bonferroni corrections were made in order to keep 
the level of significance. 
 
A correlation test was performed between the different ∆pKi values (all related to atropine) for 
the selective antagonists determined experimentally in this study and calculated from pKi values 
published by others (presented in table 4). An estimated average of the published data for each 
antagonist was used in the test. A one-tailed Pearson correlation test was performed in GraphPad 
Prism® version 4 (GraphPad Software, CA, USA) since a positive correlation was estimated 
between the experimental data and the published data. R square values and P values were used to 
evaluate the correlation test. 
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4 RESULTS 
 
This binding study is a part of the ongoing project with muscarinic acetylcholine receptors in 
congestive heart failure at the Department of Pharmacology, University of Oslo. This study is 
related to a functional study by Hussain et al. (unpublished).  
4.1 Characteristics of Sham and CHF animals 
 
The post infarction heart failure model in rats induced by coronary artery ligation showed 
hemodynamic changes characteristic for dilated cardiomyopathy with significantly increased 
heart weight including significantly increased right ventricle (RV) weight, elevated LVEDP ≥ 15 
mmHg and decreased left ventricular systolic pressure (LVSP) which correspond to observed 
characteristics by others in this model (Sjaastad et al., 2000;Sjaastad et al., 2003;Tveit, 2003). 
Pulmonary congestion, an important sign of congestive heart failure, was also shown in the CHF 
rats by significantly increased lung weight. Animal characteristics are summarised in table 5.   
 
Table 5: Animal characteristics. The values are given as mean ± S.E.M. RV, right ventricle; LVEDP, left 
ventricular end diastolic pressure; LVSP, left ventricular systolic pressure. * P < 0.05 ** P < 0.001 
 # Data obtained for only n = 7 in the Sham group, ## Data obtained for only n = 23 in the CHF group 
 
      Sham    CHF 
                (n = 14)   (n = 24) 
 
Body weight, g    429 ± 13   386 ± 9* 
Heart weight, g    1.46 ± 0.05   2.59 ± 0.11** 
Heart weight/body weight, g/kg  3.43 ± 0.10   6.79 ± 0.30** 
RV weight, g#     0.21 ± 0.01   0.44 ± 0.03** 
Lung weight, g##    1.49 ± 0.04   4.01 ± 0.24** 
LVEDP, mmHg#    7 ± 0.8    28 ± 1.6** 
LVSP, mmHg#    130 ± 4   102 ± 3* 
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4.2 Binding characteristics of muscarinic acetylcholine receptors 
4.2.1 Incubation time 
 
For the results of the binding experiments to be valid, the experimental conditions have to be 
appropriate to allow the binding between the radioligand and the receptor to reach equilibrium for 
all the chosen concentrations of radioligand used in the assay. This is especially critical for the 
lowest concentrations, which require the longest time to reach equilibrium, according to equation 
(2) (part 3.4.1 “Fundamentals of receptor binding assays”). The incubation time was chosen to 
120 minutes (Myslivecek et al., 2003a). To confirm that the time chosen was appropriate under 
the given experimental conditions, specific binding was determined after 90, 120 and 150 
minutes, for three low concentrations of the radioligand, [3H]QNB (0.06 nmol/L, 0.22 nmol/L 
and 0.89 nmol/L) in ventricular membranes from normal, Sham and CHF rats.  
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Figure 11: Time course of specific binding. Cardiac ventricular membranes from normal, Sham and CHF 
myocardium were incubated for 90, 120 and 150 minutes at 24 °C with 0.06 nmol/L, 0.22 nmol/L and 0.89 nmol/L 
[3H]QNB. The figure shows the mean of two separate, similar experiments in each tissue. 
 
As shown in figure 11, the specific binding of the [3H]QNB for the mAChRs has reached a 
plateau at 120 minutes of incubation with the chosen concentrations of the radioligand. No 
further significant increase in specific binding was shown after 120 minutes. This indicated that 
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the incubation time chosen was long enough to reach equilibrium in the formation of receptor-
radioligand complexes from mAChRs and free [3H]QNB. 
 
4.2.2 Binding properties of [3H]QNB and muscarinic acetylcholine receptor 
density in rat ventricular membranes 
 
It was of interest to determine the affinity of the radioligand, [3H]QNB for the mAChRs and to 
determine the density of mAChRs in ventricular membranes from normal, sham operated and 
CHF rats and to compare the results from the different tissues to look for changes in the binding 
characteristics. 
 
The specific binding of [3H]QNB to muscarinic acetylcholine receptors in rat ventricular 
membranes displayed high affinity and was saturable as shown by a hyperbola given by equation 
(5) in figure 12. The non-specific binding, defined as non-displaceable binding in the presence of 
1 µmol/L atropine, was non-saturable in the range of [3H]QNB concentrations used. The non-
specific binding was considered linear related to the [3H]QNB concentrations. 
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Figure 12: Saturation curve. The figure shows one representative saturation curve from one experiment in addition 
to the binding curve of the total binding and the non-specific binding of [3H]QNB to binding sites in cardiac 
ventricular membranes from a CHF rat. 
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Scatchard plots of the data, one example showed in figure 13, gave a straight line, indicating a 
single population of receptors. This is in concert with the finding that the radioligand, [3H]QNB, 
bound with equal affinity to the different mAChR subtypes (Myslivecek and Trojan, 2003b). 
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Figure 13: Scatchard plot. The figure shows the Scatchard plot for the same experiments as in figure 12. 
 
There seems to be no significant change in the dissociation constant of [3H]QNB for mAChRs in 
CHF rats compared to sham operated rats (P > 0.05) (table 6). Bmax of mAChRs binding sites 
were increased by 26% in ventricular membranes from rats with CHF compared to sham operated 
rats, but this increase was not significant (P = 0.085) (table 6 and figure 14). There was, however, 
a significant increase by 29% in mAChR density between sham operated rats and normal rats  
(P = 0.016). 
 
Table 6: Characteristics of muscarinic acetylcholine receptors in myocardium from normal, Sham and CHF 
rats measured by receptor binding.  
Values are given as means ± SEM. Kd is given in nmol/L and Bmax in fmol/mg protein.  
 
               Normal             Sham             CHF 
     (n = 6)             (n = 6)           (n = 6) 
 
Kd (nmol/L)           0.20 ± 0.02        0.18 ± 0.06      0.15 ± 0.04 
Bmax (fmol/mg protein)          108 ± 2          139 ± 11        175 ± 18 
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Figure 14: Muscarinic acetylcholine receptor density in normal, Sham and CHF rats. Values are given as Bmax 
in fmol/mg protein. 
 
 
4.2.3 Effects of guanine nucleotides on high-affinity agonist binding  
 
Muscarinic acetylcholine receptor regulation of several cellular processes, including adenylyl 
cyclase activity, is mediated by G proteins. In this study, it was of interest to study the high-
affinity binding of an agonist and its regulation by guanine nucleotides as an index of the 
interactions between the mAChRs and G proteins.  
 
Carbachol was used as a non-selective agonist for the mAChRs and the [3H]QNB binding was 
inhibited by carbachol in a dose-dependent manner (figure 15). The competition curve of 
carbachol was best fit to a two-site model in the absence of GTP in normal, Sham and CHF rats 
(P < 0.05), indicating the presence of both high- and low-affinity binding sites. There were no 
significant differences in the pKi values for either high- and low-affinity binding sites or in the 
distribution between the two binding sites in normal, Sham and CHF rats (P > 0.05) (table 7). 
 
In the presence of GTP added in excess, the G proteins get activated. GTP bound to the G 
proteins prevents the interaction with the receptor and hence make a shift of the carbachol 
competition curves to a higher agonist concentration (see figure 15 for examples and figure 16 for 
theoretical constructed competition curves based on the average data for fractions and pKi 
values). The data did not fit significantly better to a two-site model than a one-site model for the 
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competition curves of carbachol in the presence of GTP (P > 0.05) in three of four experiments in 
ventricular membranes from normal rats, while a two-site model was preferred in four of eight 
experiments in Sham rats and in six of eight experiments in CHF rats (P < 0.05). There were no 
significant differences in the pKi values between normal, Sham and CHF rats in the presence of 
GTP when all the binding experiments were presented as a one-site model (table 7).   
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Figure 15: Dose-dependent competition by carbachol of [3H]QNB binding to mAChR sites in ventricular 
membranes from normal rats (A), Sham rats (B) and CHF rats (C and D). Data are from single representative 
experiments. Panels A, B and C represent experiments where the carbachol competition curves were best fit to a 
two-site model in the absence of GTP and a one-site model in the presence of GTP. Panel D shows one of the 
experiments where a two-site model was preferred in the presence of GTP in ventricular membranes from CHF rats. 
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Table 7: Displacement of [3H]QNB binding with carbachol to myocardial muscarinic acetylcholine receptors 
in normal rats, sham operated rats and rats with congestive heart failure. Values are given as means ± S.E.M. 
Affinity for the high affinity site (KiH) and affinity for the low affinity site (KiL) are given as pKi  (–log Ki). FH, 
fraction high affinity; FL, fraction low affinity. * Data in the presence of GTP in CHF rats analysed by a one-site 
model. ** Data in the presence of GTP in CHF rats analysed by a two-site model. 
 
  Normal  Sham    CHF 
  (n = 4)   (n = 8)   (n = 8) 
 
In the absence  
of GTP:    
FH   0.42 ± 0.06  0.45 ± 0.07  0.34 ± 0.07  
FL   0.58 ± 0.06  0.55 ± 0.07  0.66 ± 0.07 
pKiH  6.33 ± 0.21  6.42 ± 0.23  6.79 ± 0.29 
pKiL  4.41 ± 0.11  4.52 ± 0.14  4.62 ± 0.15 
 
In the presence  
of 100 µmol/L GTP:      *   ** 
FH   0   0   0   0.38 ± 0.09 
FL   1.00   1.00   1.00   0.62 ± 0.09 
pKiH   -   -   -   6.09 ± 0.17   
pKiL   4.88 ± 0.05  5.24 ± 0.11  5.20 ± 0.16  4.63 ± 0.13 
 
From the data presented above, theoretical competition curves have been made based on the 
calculated averages of the fractions and the pKi values for the high- and low affinity sites in the 
absence and the presence of GTP from normal, Sham and CHF rats. A two-site model for the 
competition curve of carbachol was chosen in the absence of GTP and a one-site model for the 
competition curve of carbachol in the presence of GTP (figure 16 A-C). However, in CHF rats, a 
two-site model was preferred in six of eight experiments in the presence of GTP. Therefore, it 
was decided to recalculate the data and make a theoretical competition curve based on the 
preferred two-site model in the presence of GTP for the CHF rats (table 7). The result is 
presented in figure 16 D. 
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Figure 16: Theoretical calculated dose-dependent competition by carbachol of [3H]QNB binding to mAChR 
binding sites in ventricular membranes from normal (A), Sham (B) and CHF rats (C and D). The curves are 
based on the calculated averages of the fractions and the pKi values for the high- and the low affinity sites in the 
absence and the presence of GTP in ventricular membranes from normal, Sham and CHF rats. A two-site model was 
chosen for the competition curves in the absence of GTP, and a one-site model was chosen for the competition 
curves in the presence of GTP in A, B and C.  However, in D a two-site model is presented for the competition curve 
in the presence of GTP in CHF rats. 
 
Some additional experiments were performed in normal rats with carbachol in the absence and 
the presence of guanosine 5'-[β,γ-imido]triphosphate, Gpp(NH)p, a non-hydrolysable analog of 
GTP,  and the results were similar to the already presented data, confirming that the GTP 
concentration chosen gave maximal effect (data not shown).   
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4.2.4 Muscarinic acetylcholine receptor subtypes in rat cardiac ventricles 
 
To identify which mAChR subtypes are present in ventricular membranes in rats, different 
antagonists with high affinity for M1 mAChRs (nitrocaramiphen), M2 mAChRs (AF-DX 116) 
and M3 mAChRs (4-DAMP) were used, chosen in accordance to the functional study (Hussain  
et al. unpublished). In addition, an antagonist for M4 mAChRs (tropicamide) was used. Atropine 
was used as a reference substance for displacing mAChRs. Atropine inhibited the [3H]QNB 
binding to mAChRs sites in a dose-dependent manner (figure 17). The competition curves were 
best fitted to a one-site model, and the pKi values are presented in table 8. There were no 
significant changes in the pKi values in congestive heart failure compared to the control group. A 
concentration of 1.0 µmol/L atropine displaced approximately 99% of the specific binding, and 
therefore this concentration of atropine was used to experimentally determine the non-specific, 
non-displaceable [3H]QNB binding. 
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Figure 17: Competition curves. Inhibition of [3H]QNB binding to mAChRs sites in cardiac ventricular membranes 
by atropine, nitrocaramiphen, AF-DX 116, 4-DAMP and tropicamide in normal (A), sham operated (B) and CHF 
rats (C). The competition curves are from single, representative experiments. 
 
Nitrocaramiphen, AF-DX 116, 4-DAMP and tropicamide all displaced [3H]QNB binding in a 
dose-dependent manner. The competition curves for all the antagonists were best fitted to a one-
site model for normal, Sham and CHF rats as shown in figure 17 (P > 0.05). The pKi values are 
presented in table 8. There were no significant differences in the pKi values comparing CHF to 
Sham and normal rats for any of the antagonists (P > 0.05). 
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Table 8: Competiton between [3H]QNB and different antagonists for binding to myocardial muscarinic 
acetylcholine receptor sites in normal rats, sham operated rats and rats with congestive heart failure. Values 
are given as mean ± S.E.M. Ligand affinities are given as pKi values (-log Ki). 
 
       Normal       Sham   CHF 
 
Atropine (n = 3)  8.45 ± 0.06  8.40 ± 0.06        8.45 ± 0.05 
Nitrocaramiphen (n = 5) 5.67 ± 0.03  5.88 ± 0.06        6.04 ± 0.14 
AF-DX 116 (n = 3)  5.93 ± 0.04  5.97 ± 0.13        6.12 ± 0.11 
4-DAMP (n = 3)  7.79 ± 0.06  7.96 ± 0.09        7.99 ± 0.08 
Tropicamide (n = 4)  7.05 ± 0.04  7.11 ± 0.08        7.25 ± 0.04  
  
 
All the ligands used in the competition binding experiments, agonist (only carbachol in this 
study) and antagonists, displaced the radioligand, [3H]QNB, to the similar non-specific, non-
displaceable binding level. This common characteristic of all the ligands is an important 
indication that the radioligand binding sites represent the mAChRs present in the tissue. 
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5 DISCUSSION 
 
Muscarinic acetylcholine receptors are important receptors in the dynamic regulation of the heart 
by the autonomic nervous system. This regulation may change during diseased states like 
congestive heart failure. Knowledge of the basal mechanisms is necessary to understand the 
pathophysiology of CHF, and it is important for further drug development.  
 
5.1 Experimental considerations 
 
Radioligand binding is a widely used pharmacological method to define and characterise the 
binding sites of interest that interact with a ligand that can be radiolabelled. In this study this 
method was used to examine characteristics of muscarinic acetylcholine receptors binding sites. 
 
Many experimental conditions may influence the receptor-radioligand binding and the  
G protein interaction with the receptor, such as pH and temperature, and also contribute to 
changes in the receptor level, such as the presence of proteases in the tissue. Therefore, it is 
important to optimise the experimental conditions to obtain the correct determination of the 
receptor characteristics. How this process has been performed, can vary between different 
research groups and the results can be difficult to compare because the procedure for making the 
membrane preparation and other experimental conditions in the binding assay may be different. 
 
In binding assays the radioligand will bind to all the available binding sites with affinity relevant 
for the actual concentration of radioligand. Therefore, the calculations of the density of the 
radioligand binding sites, the affinity of the radioligand and the pKi values for the different 
agonists and antagonists to the receptors will represent the total amount of binding sites present 
in the tissue. In functional studies, a certain receptor mediated response is measured which is 
mediated by the signalling cascade downstream of one or several of the activated receptor 
subtypes present in the tissue and not necessary the whole receptor population which is available 
for the radioligand in binding studies. This may cause differences in the estimated pKi values 
obtained from functional studies compared to receptor binding studies. This is important to bear 
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in mind when trying to explain a functional phenomenon, such as an inotropic effect mediated by 
CCh in CHF rats.  
 
In receptor binding studies, the results represent the binding sites for the radioligand chosen. In 
this study, there is no measurement of functional response mediated by the same binding sites 
which could have confirmed that the binding sites represent muscarinic acetylcholine receptors 
except for the competition binding experiments with inhibition of [3H]QNB binding by agonist in 
the absence and the presence of GTP. In these experiments, a conformational change in the 
binding site has been shown and this phenomenon is well-known for agonist binding to receptors. 
However, this study is strengthened by the finding that all the ligands used, both agonist and 
antagonists, displaced the radioligand binding to the similar level of non-specific, non-
displaceable binding. All the ligands used displaced [3H]QNB from the same pool of receptors, 
representing one or several mAChR subtypes. 
 
5.2 Binding properties of [3H]QNB and muscarinic acetylcholine 
receptor density in rat ventricular membranes 
 
The affinity of the radioligand, [3H]QNB, which is a non-selective antagonist for the mAChRs, 
was not significantly changed in ventricle membranes from rats with CHF compared to sham 
operated rats and normal rats. This fits well with already published data from heart in both rat and 
dog (Fu et al., 1993;Dunlap et al., 2003). The affinity of [3H]QNB was also within the range of 
previously reported Kd values in heart from rats (Oki et al., 2001;Dunlap et al., 2003;Myslivecek 
and Trojan, 2003b). 
 
In this infarction induced heart failure model in rats, the binding data may indicate an increase in 
mAChRs in ventricles from rats with CHF compared to Sham rats, but the alteration was not 
statistically significant. The same was observed in cardiac ventricular tissue from rat by Fu et al. 
(1993) even though the estimated density of mAChRs was generally higher in that study than 
found in the present work. This may be caused by different experimental conditions as described 
in part 5.1 “Experimental considerations”. In various other models of heart failure mAChR 
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density in ventricular myocardium has been reported to be reduced in a dog model of left 
ventricular failure due to aortic banding (Vatner et al., 1988). Similar results were obtained in 
rats with aortic banding (Mertens et al., 1995). In other studies of animal models with induced 
heart failure, the mAChR density has been showed to be increased (Vatner et al., 1996). The 
receptor density in human cardiac tissue with heart failure has been shown to be unchanged in 
patients with end-stage heart failure due to idiopathic dilated cardiomyopathy or to ischemic 
cardiomyopathy while in the same patients β-AR numbers were significantly reduced (Böhm et 
al., 1990a;Böhm et al., 1990b). However, in an in vivo positron emission tomography (PET) 
study, cardiac mAChRs were shown to be slightly, but significantly increased in patients with 
congestive heart failure (Le Guludec et al., 1997).  
 
From the published data presented above, there seem to be variations in the results obtained in 
the different studies in the density of mAChR in heart failure compared to a control group. In 
some of the studies, the change in density of mAChR in heart failure seems to some extent to be 
related to the cause of heart failure. The tendency of increased mAChRs demonstrated in this 
study, in myocardium from rats with CHF due to myocardial infarction, might be some of the 
mechanism for the observed CCh induced positive inotropic effect in CHF rats (Hussain et al. 
unpublished). 
 
5.3 Effects of guanine nucleotides on high-affinity agonist binding  
 
Muscarinic acetylcholine receptors seem to be a population of receptors displaying both high and 
low affinity for agonists. The presence of guanine nucleotides promotes the conversion of 
receptors from a high-affinity to a low-affinity state (Rosenberger et al., 1980). This leads to 
conformational states where receptors with high affinity for the agonist are coupled to G proteins, 
whereas receptors with low affinity for the agonist are uncoupled from the G protein (Aronstam 
and Narayanan, 1988). When comparing the fractions of receptors displaying high-affinity 
agonist binding in the absence of GTP between Sham and CHF rats, it is possible to provide 
information about receptor association with G proteins in congestive heart failure compared to 
the control group. The ability of guanine nucleotides to convert the receptors to low-affinity 
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states can also bring some information about the interaction between the receptors and the G 
proteins. 
 
In this study there seemed to be no shift in the distribution between high- and low-affinity 
binding sites for carbachol in the absence of GTP in ventricular membranes from CHF rats 
compared to Sham and normal rats. The similar distribution between high and low affinity 
binding sites has also been reported in CHF rats and control group by Fu et al. (1993). The pKi 
values for the high and low affinity in the absence of GTP were not significantly different in CHF 
rats compared to Sham and normal rats. This indicates that there is no change in the affinity for 
carbachol in CHF rats compared to Sham which was one of the hypotheses for the mechanisms of 
the carbachol induced inotropic effect in CHF rats (Hussain et al. unpublished). 
 
In normal and Sham rats in the presence of GTP, a one site model was preferred in most of the 
experiments. This was expected according to the biological explanation of a shift in affinity for 
agonist in the presence of GTP since GTP bound to the G protein is expected to initiate the 
dissociation of the G protein from the receptor causing a conformational change of the receptor.  
When all the data were analysed by a one-site model in the presence of GTP, there were no 
significant changes in the low affinity between the different groups and there seemed to be no 
change in sensitivity to GTP. When comparing the low affinity pKi values in the absence and the 
presence of GTP in normal, Sham and CHF rats, the pKi values in the presence of GTP are 
nominally higher than in the absence of GTP. This may be caused by the mathematical 
calculations of a biological phenomenon including a small portion of high-affinity binding sites.     
 
In the CHF rats, a one-site model of agonist binding in the presence of GTP did not seem to be 
the optimal presentation. In six of eight experiments in ventricular membranes from CHF rats, a 
two-site model was significantly better fitted to the data. When constructing competition curves 
based on the calculated averages of the fractions and the pKi values using a two-site model both 
in the absence and the presence of GTP, the phenomenon of shift of the competition curves to a 
higher agonist concentration in the presence of GTP was still present, but to a lesser extent. A 
significant fraction of high-affinity binding sites was still present even if the pKi value was 
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decreased. Thus, in the CHF rats, there may be a lower sensitivity to GTP. This finding was not 
further explored in this study, and the mechanism has to be further examined.  
 
Since GTP can be hydrolyzed by GTPases present in the tissue, some additional experiments 
were done with Gpp(NH)p, a non-hydrolysable analogue of GTP, in normal rats. Since the results 
were not different from those shown with GTP, these experiments confirmed that the 
concentration of GTP used was sufficient to obtain maximal effect.  
 
5.4 Muscarinic acetylcholine receptor subtypes in rat cardiac 
ventricles 
 
Because of the indication of increased density of mAChRs in heart failure, it was of particular 
interest to identify which mAChR subtypes are present in ventricular membranes in normal, 
Sham and CHF rats. Altered expression of the mAChR subtypes may also be of interest since 
they mediate different effects: the M2 and M4 mAChRs are coupled to Gi, resulting in a negative 
inotropic and chronotropic effect; while the M1, M3 and M5 mAChRs are Gq coupled and are 
expected to mediate a positive inotropic effect. Alterations in mAChR subtype expression may 
also be part of the explanation for the observed CCh induced positive inotropic effect in heart 
failure (Hussain et al. unpublished). Different selective antagonists for M1, M2, M3 and M4 
mAChRs were used as tools to determine the receptor profile present in ventricles in normal, 
Sham and CHF rats, and if present, to detect changes in the receptor subtype profile in CHF rats 
compared to sham operated and normal rats. 
 
Atropine was used as reference substance for displacement of [3H]QNB since it is a commonly 
used non-selective antagonist for mAChRs. All the other ligands displaced the radioligand to the 
same level as atropine, indicating that the displaced radioligand represented the specific binding 
to mAChRs only even at high concentrations of the unlabelled ligands. The competition curve of 
atropine was analysed to best fit a one-site binding model, as expected. However, the calculated 
pKi values of atropine from normal, Sham and CHF rats were approximately a half log unit lower 
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than the published data (table 4). This difference in affinity was taken into account when the 
receptor profile was analysed as described below. 
 
The competition curves of the selective antagonists fitted a one-site binding model, which often 
indicate only one receptor subtype present in the tissue, or that the antagonists used in the study, 
are not able to distinguish between the different receptor subtypes. This is further discussed 
below.  
 
The pKi values for nitrocaramiphen in this study were calculated to 5.67 in normal, 5.88 in Sham 
and 6.04 in CHF rats, which was lower than the affinity published for nitrocaramiphen to M1 
mAChRs (table 4) and the affinity obtained in the functional study performed by Hussain et al. 
(unpublished) which was 7.57 in CHF rats. The pKi values from the binding assays do not 
support the presence of M1 mAChR in the ventricle in rats neither in CHF rats nor normal or 
Sham rats, but the measured affinities of nitrocaramiphen may fit to some extent with the affinity 
published for M2 mAChRs for nitrocaramiphen (table 4). The M2 mAChR antagonist, AF-DX 
116, displaced [3H]QNB with a low affinity compared to published affinity values for M2 
mAChRs (table 4). This was somewhat surprising, since one would expect to detect M2 mAChRs 
to some degree since there has been a common agreement of this mAChR subtype as the 
dominant subtype present in the heart. The pKi values were in this study calculated to 5.93 in 
normal rats, 5.97 in Sham rats and 6.12 in CHF rats. The affinities were also low compared to the 
pKi values obtained in CHF rats in the functional experiments, 7.3 (Hussain et al. unpublished). 
The affinities of 4-DAMP to the mAChRs in this study were 7.79 in normal rats, 7.96 in Sham 
rats and 7.99 in CHF rats, which were clearly lower than the published affinities for 4-DAMP. 
Thus, our data do not support the presence of M3 mAChRs as the dominant mAChR subtype 
based on the affinity of this antagonist separately (table 4). The pKi value from the functional 
experiments was 8.38 in CHF rats (Hussain et al. unpublished). However, the affinity of  
4-DAMP can be compatible with the presence of M2 mAChRs according to the published data 
(table 4). Tropicamide, which is the antagonist used with high affinity for M4 mAChRs, showed 
affinities of 7.05 in normal rats, 7.11 in Sham rats and 7.25 in CHF rats in this study. The 
affinities do not strongly support the presence of M4 mAChRs in the ventricles, but tropicamide 
has almost the similar affinity to the other mAChR subtypes. Therefore, it is not possible to 
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distinguish between the other mAChR subtypes by using tropicamide. Functional experiments 
with tropicamide were not performed when this thesis was written.  
 
In general, based on the pKi values calculated from this receptor binding study compared to the 
pKi values obtained from the functional experiments (Hussain et al. unpublished), the data 
obtained seem to indicate that in receptor binding experiments the radioligand labels a different 
population of mAChRs than the mAChR subtypes mediating the observed positive inotropic 
effect by CCh in CHF rats. This can be explained as previously stated by only a fraction of the 
present mAChRs in the ventricular membranes mediating the observed effect and thus only the 
characteristics of those receptors are exposed in functional studies.  
 
To identify the mAChRs present in the ventricles in rats, the result can not completely rely on 
evaluation of affinity of a single antagonist for one mAChR subtype. The whole profile of 
affinities of the different antagonists has to be considered. Therefore, a correlation test was done 
between the obtained pKi values for all the selective antagonists in the receptor binding study and 
the published data for the antagonists in relation to identified mAChR subtypes. No published 
pKi values for nitrocaramiphen to M4 mAChRs and M5 mAChRs and tropicamide to M5 
mAChRs were obtained from the published data. Because of this, a correlation test could only be 
made from the pKi values obtained from the receptor binding experiments and the published data 
for M1, M2 and M3 mAChRs. Since the pKi values for atropine obtained in this study was lower 
than the published data (table 4), ∆pKi values for all the selective antagonists were calculated 
relative to the pKi value of atropine in normal, Sham and CHF rats. A Pearson correlation was 
performed and the results are presented in figure 18 A-I. The binding profile for the antagonists 
in normal, Sham and CHF rats seems to be best correlated with the M2 mAChRs with r square 
values of 0.84, 0.82 and 0.80 and P values of 0.04, 0.05 and 0.05, respectively. This fits well with 
the theory that M2 mAChRs are the dominant mAChR subtype expressed in the heart. The 
presence of M3 mAChRs in the ventricles can not be completely excluded based on the result 
from the correlation test with r square values of 0.67, 0.74 and 0.73 and P values of 0.09, 0.07 
and 0.07 in normal, Sham and CHF rats, respectively, but it does not seem to be the dominant 
mAChR subtype. As previously described, a functional role of M3 mAChRs has been 
demonstrated in both rat and human heart (Ponicke et al., 2003;Wang et al., 2004). From the 
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correlation test, the probability of the presence of M1 mAChRs seems to be low based on the 
obtained data. However, at the mRNA level, M1 and M3 mAChRs seem to constitute only a small 
fraction of the mAChRs in the heart, 1% and 3%, respectively (Krejci and Tucek, 2002). Studies 
performed by both Krejci & Tucek (2002) and Tveit et al. (2003) detected mRNA for all the 
mAChR subtypes in left ventricle in rat, indicating that M2 mAChRs are not the only mAChRs in 
the heart, at least not at the mRNA level. If the same mAChR subtype profile is present at the 
protein level, it can be difficult to detect with receptor binding performed with the selectivity of 
the synthetic ligands available today. There exist no ligands with high affinity for M5 mAChRs, 
and the already existing antagonists for the other mAChR subtypes seem to show varying extents 
of overlap in affinity between the different subtypes. The data obtained in this study seem to 
indicate that M2 mAChRs are the main mAChR subtype in rat ventricles. Based on other 
functional and biochemical studies, there is probably a mixture of several mAChR subtypes, 
which may also be present in the tissue examined in this study. However, the tools currently 
available may not be adequate to determine this in binding studies. 
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Figure 18: Correlation curves between ∆pKi values obtained from the experimental data in this study and the 
∆pKi values from the published data (table 4) for M1 mAChRs (A-C), M2 mAChRs (D-F) and M3 mAChRs, 
(G-I) in ventricular membranes from normal, Sham and CHF rats. Values are presented as ∆pKi values (± 
S.E.M for the experimental data). A one-tailed Pearson correlation test was performed since a positive correlation 
was estimated. 
 
The fact that the available selective antagonists for mAChR subtypes may not be selective 
enough to identify low levels of certain subtypes and hence detect small changes in receptor 
subtypes is important to bear in mind when evaluating and comparing the receptor subtype 
profile between CHF rats and normal and Sham rats. There were no significant differences in the 
pKi values for any of the antagonists in CHF rats compared to normal and Sham rats (P > 0.05), 
which indicated no measurable changes in the mAChR profile in ventricular membranes from 
CHF rats compared to Sham and normal rats. This was also shown in the correlation test with 
very similar r square values from normal, Sham and CHF rats. The result from the study by Tveit 
et al. (2003) indicated that the M2 mAChR mRNA level did not change in an infarction induced 
CHF model in rats, which was the same model as used in this study. Giessler et al. (1999) also 
claimed that cardiac M2 mAChR density and functional responsiveness in failing human heart 
were not considerably changed. However, Tveit et al. (2003) showed an increase at the mRNA 
level of both M3 mAChRs and M4 mAChRs in CHF compared to Sham rats. This might indicate 
that these two subtypes of mAChRs may become more important in CHF in rats. The functional 
positive inotropic effect of CCh in papillary muscles from CHF rats observed in our lab (Hussain 
et al. unpublished) seemed to have characteristics indicating that the effect was mediated by a Gq 
coupled receptor, possibly implicating the M3 mAChR. However, the increased level of M3 and 
M4 mAChR at the mRNA level does not necessarily result in increased receptor proteins. Even if 
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a change was present, the increased fraction may be too small to be detected in receptor binding 
studies with the selective antagonists available today.  
 
By using pharmacological techniques like receptor binding assays, the result will rely on the 
identification of receptor profiles, compared with receptor binding profiles usually quantified for 
receptor ligands acting on a pure and homogeneous receptor population. This can be done by 
using transfected cell lines expressing one particular mAChR gene. However, caution has to be 
shown when using this comparison because an assumption that the cloned receptor expressed in 
the cell line will have the same characteristics as the native expressed receptor in the intact 
organism may be wrong. Caulfield suggested in his paper from 1993 that mAChR amino acid 
sequences have sites that are likely targets for post-translational modification, such as 
phosphorylation or glycocylation, and the native cell complement of moieties that can couple to 
the receptor, such as G protein, may result in differences in ligand-binding affinities between 
receptors expressed in transfected cells and in native cells. It should also be noted that several 
antagonists, such as gallamine, allosterically modulate mAChR function, notably at the M2 
mAChRs (Eglen and Watson, 1996;Christopoulos and Kenakin, 2002). This may complicate the 
determination of their apparent affinity and thus interpretation of subtype selectivity. 
  
 
5.5 Future Research 
 
For the understanding of pathophysiology of congestive heart failure, it would be of interest to 
examine the mechanism causing the decreased sensitivity of G proteins for guanine nucleotides in 
ventricles from rats with congestive heart failure. The first approach may be to determine which 
G protein is present in the ventricle and if there are changes in the G protein type or recruitment 
of other G proteins to the cell membranes in congestive heart failure compared to a control group. 
 
To identify mAChR subtypes in ventricles in rats by a pharmacological method like receptor 
binding, there seems to be a need for new synthesised selective antagonists for the different 
mAChR subtypes with higher selectivity between the mAChR subtypes than the “selective” 
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antagonists available today. It may then be possible to detect the presence of even small amounts 
of subtypes and changes in receptor profiles if present in diseased states like congestive heart 
failure. It would also have been of interest to have radiolabelled selective antagonists which could 
make it possible to label the mAChRs subtypes and to do competition binding experiments with 
another unlabelled selective antagonist. Then the calculated pKi values would make a more 
precise determination of the receptor profile. To be able to correlate the affinities of the 
antagonist with affinities for each mAChR subtypes, the affinity for each of the antagonists had 
to be determined separately for each mAChR subtype in a cell line with over expression of the 
different mAChR subtypes. 
 
Until more satisfying selective antagonists have been developed, other biochemical methods may 
be used to identify the mAChR profile at receptor level in ventricles from rat, such as antibodies 
which recognise each mAChR subtype and can quantitatively determine the amount of each 
subtype present in the tissue.  
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6 CONCLUSION 
 
In conclusion, it has been demonstrated that there might be no significant change in muscarinic 
acetylcholine receptor density in ventricles from rats with congestive heart failure induced by 
infarction compared to control group, even though a non-significant increase was observed. No 
change in affinity for the agonist carbachol seemed to be present in CHF rats compared to control 
group in the absence of guanine nucleotides. However, the mAChRs in the ventricles from CHF 
rats seemed to have lesser sensitivity to GTP than mAChRs in the ventricles from normal and 
Sham rats. The mechanism is still unknown. The dominant mAChRs in the ventricles in rat 
seemed to be M2 mAChRs, and no change in mAChR subtype profile in the ventricles in CHF 
rats compared to control group was observed. However, the selective antagonists for the different 
mAChR subtypes, currently available today, might not be able to detect small fractions of 
mAChR subtypes even if they were present in the cardiac ventricular membranes, or to detect 
small differences in the expression of receptor proteins in congestive heart failure compared to 
control group. 
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8 APPENDIX 
8.1 Materials and recipes 
8.1.1 Chemicals and reagents 
 
Chemical/Reagent Abbreviation Manifacturer Cat.no 
1,10-phenantroline monohydrate  Sigma P9375 
1,1-Dimethyl-4-
diphenylacetoxypiperidinium iodide  
4-DAMP Tocris 0482 
11-[[2-[(Diethylamino)methyl]-1-
piperidinyl]acetyl]-5,11-dihydro-6H-
pyrido[2,3-b][1,4]benzodiazepin-6-
one  
AF-DX 116 Tocris 1105 
1-quinacliinyl[phenyl-43H] benzilate [3H]QNB Amersham TRK 604 
2-Diethylaminoethyl 1-(4-
nitrophenyl)cyclopentanecarboxylate 
hydrochloride 11-[[2-
[(Diethylamino)methyl]-1-
piperidinyl]acetyl]-5,11-dihydro-6H-
pyrido[2,3-b][1,4]benzodiazepin-6-
one 
Nitrocaramiphen  Tocris 0469 
Absolute ethanol  Arcus - 
Atropine sulfate salt  Sigma A0257 
BCA Protein Assay Kit  Uptima UP40840A 
Carbamoylcholine chloride, 
carbachol 
CCh Sigma C4382 
dH2O  - - 
Dimethyl sulfoxide DMSO Sigma D5879 
Ethylenedinitrilo tetraacetic acid EDTA Merck  8418.0250 
Guanosine 5'-[β,γ-
imido]triphosphate trisodium salt 
Gpp(NH)p Sigma G0635 
Guanosine 5'-triphosphate sodium 
salt hydrate 
GTP Sigma G8877  
Hydrochloric acid fuming 37% HCl Merck 1.00317.1000 
Magnesium chloride hexahydrate MgCl x 6H2O Merck 5833.1000 
MicroScint  Packard 6013611 
N-Ethyl-3-hydroxy-2-phenyl-N-
(pyridinylmethyl)propanamide 
Tropicamide Tocris 0909 
Opti-fluor  Packard 6013199 
Phenylmethanesulfonyl fluorid PMSF Sigma P7626 
Polyethyleneimine 50% solution  Sigma P3143 
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Potassium chloride KCl Merck 1.04936.1000 
Sodium chloride NaCl Merck 1.06404.0500 
Tris(hydroxmetyl)aminomethan Tris Merck 1.08382.0500 
 
 
8.1.2 Content of buffers 
 
Reagent Ingredients 
Buffer for tissue preparation and incubation 
(TME buffer) 
50 mmol/L Tris 
10 nmol/L MgCl2 x 6 H2O 
1 mmol/L EDTA 
pH adjusted to 7.4 at room temperature by 
2 mol/L HCl 
Buffer for tissue preparation 
(TME buffer with protease inhibitors) 
50 mmol/L Tris 
10 nmol/L MgCl2 x 6 H2O 
1 mmol/L EDTA 
100 µmol/L PMSF 
100 µmol/L phenantroline 
pH adjusted to 7.4 at room temperature by  
2 M HCl 
Washing buffer 10 mmol/L Tris 
2 mmol/L MgCl2 x 6 H2O 
pH adjusted to 7.0 at room temperature by 
hydrochloric acid fuming 37% 
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8.2 Protocols 
8.2.1 Membrane preparation 
 
1. Add a given volume of TME buffer with protease inhibitors, approximately 2/3 of the 
total volume, into a glass-glass homogeniser on ice. 
2. Weigh one part powder of cardiac ventricular tissue in plastic equipment precooled in 
liquid nitrogen. Transfer immediately the cardiac ventricular tissue into the glass-glass 
homogeniser. (The amount of cardiac ventricular tissue needed for each experiment has to 
be calculated based on the final volume of membrane preparation).   
3. Add the rest of the TME buffer with protease inhibitors into the glass-glass homogeniser, 
at a total volume of 19 volumes the weight of the cardiac ventricular tissue.  
4. Set the homogeniser, Tri-R Stri-R model S 63 C (Tri-R Instruments, Inc), at level 6, and 
homogenize the sample by lifting the glass-glass homogeniser up and down 10 times or 
until the sample is homogenous. 
5. Put the glass-glass homogeniser back on ice. 
6. Transfer the homogenized membrane preparation to a suitable tube. 
7. Add an equal volume of 1 mol/L KCl as the volume of the membrane preparation. 
8. Mix the reagents thoroughly with a whirl mixer. 
9. Leave the tubes on ice for 10 minutes. 
10. Spin the membranes down at 20000 rpm for 12 minutes at 4°C with rotor 20.1 in a 
Beckman J2-MC Centrifuge (Beckman Instruments, Inc). 
11. Put the tube back on ice. 
12. Remove the supernatant and resuspend the resulting pellet in 19 volumes the weight of 
the heart tissue, in TME buffer with protease inhibitors, by using an Ultra-Turrax type TP 
18-10 (Ika Werk) at maximum speed. Lift the tube up and down 10 times and keep the 
tube on ice before repeating another 10 times of lifting the tube up and down. 
13. Repeat point 10 –12 twice but resuspend the precipitate in TME buffer instead of TME 
buffer with protease inhibitors. The last time resuspend in 16 volumes TME buffer instead 
of 19. 
14. Filter the membrane preparation through nylon mesh (pore size: 60 my).  
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15. Keep the membrane preparation on ice until use. 
 
8.2.2 Incubation 
 
1. Add the different ingredients in a cone bottom 96-well microtiterplate on ice. The reaction 
mixture in each well is described in table 9 for saturation- and competition experiments 
and experiments to study if steady state was reached. 
 
Table 9: Incubation mixture in each well in a 96-well microtiterplate in the saturation- and competition 
experiments and experiment to study the incubation time.  All the volumes are given as µL and the ingredients 
are given in the order loaded to the microtiterplate. 
 Saturation binding 
experiments 
and experiments to study the 
incubation time  
Competition binding 
experiments 
 Total  
binding 
Non-specific 
binding 
Total  
binding 
Non-specific 
binding 
Incubation buffer 
(=TME buffer) 175 µL 150 µL 150 µL
 
150 µL 
[3H]QNB 25 µL 25 µL 25 µL 25 µL 
Atropine 1 µmol/L 
(at final 
concentration)  
25 µL 25 µL 
Unlabelled ligand 25 µL  
Membrane 
preparation 
50 µL 50 µL 50 µL 50 µL 
 
 
Saturation binding experiments were performed by eight concentrations of [3H]QNB,  
0.06 nmol/L-7.2 nmol/L dissolved in TME buffer. The saturation binding experiments were 
done in triplets at each concentration. 
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The experiment to study the incubation time was performed at three critical concentrations of 
[3H]QNB, 0.056 nmol/L, 0.22 nmol/L and 0.89 nmol/L. The samples were done in triplets at 
each time point at each concentration of [3H]QNB. 
Competition binding experiments were performed with 0.89 nmol/L [3H]QNB and 
concentrations of unlabelled ligands as described in table 10. 
 
Table 10: Unlabelled ligands, vehicle in stock solutions and concentration range used in competition binding 
experiments. All the concentrations are given as final concentrations in the assay.  
Unlabelled ligand Vehicle in stock solution Concentration range 
Atropine dH2O 9.5 pmol/L – 10 µmol/L 
Nitrocaramiphen  dH2O 0.95 nmol/L – 1 mmol/L 
AF-DX 116 DMSO 95 pmol/L – 100 µmol/L 
4-DAMP DMSO 9.5 pmol/L – 10 µmol/L 
Tropicamide DMSO 95 pmol/L – 100 µmol/L 
Carbachol dH2O 9.5 nmol/L – 10 mmol/L 
 
The experiments were performed by using 21 single concentrations of each unlabelled ligand. 
Competition binding experiments with carbachol were performed in the absence and the 
presence of 100 µmol/L GTP, and some additional experiments were performed in the 
absence and the presence of 100 µmol/L Gpp(NH)p. 
2. Cover the microtiterplate with a suitable lid. 
3. Carry out the incubation in a waterbath, Grant OLS 2000 (KEBO Lab), at 24°C while 
shaking the microtiterplate at 30 strokes per minute. 
4. Make the incubation last for 120 minutes except in the experiments to study if steady state 
was reached when the incubation lasts for 90, 120 and 150 minutes. 
5. Terminate the incubation by putting the microtiterplate on ice. 
6. For each experiment, control the concentration of [3H]QNB by adding 25 µL of each 
concentration of [3H]QNB to a Nunc-tube, 5 parallels of each concentration. 
7. To each Nunc-tube add 50 µL 0.5 mol/L HCl and 1 mL Opti-Fluor. 
8. Count the tubes in a Liquid Scintillation Analyser Tri-Carb 2300 TR (Packard Instrument 
& Co). 
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8.2.3 Separation of the bound and the free radioligand and measurement of 
the amount of radioactive ligand bound 
 
1. Presoak a glassfiber filter GF/C plate in 0.3% polyethyleneimine solution. 
2. Wash the filter 4 times with 250 µL cold washing buffer in a Packard Cell Harvester 
(Packard Instrument Co.). 
3. Add the reaction mixture to the filters via the cell harvester (Packard Instrument Co.) 
4. Wash the GF/C filter plate rapidly 5 times with cold washing buffer. 
5. Dry the GF/C filter plate at 37°C for 30 minutes or until the filter is dry. 
6. Add 20 µL MicroScint liquid scintillation coctail (Packard Instrument Co.) to each well.   
7. Count the GF/C filter plate in a Packard TopCount Scintillation Counter (Packard 
Instrument Co.) 
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8.2.4 Protein quantification 
 
1. Add BCA standard in duplets, 20 µL of each, and samples in triplets, 5 µL of each, in a 
flat bottom 96-well microtiterplate according to figure 19. 
2. Add 50 parts of BCA reagent A and one part of BCA reagent B to a tray, mix the reagents 
and load 250 µL of the solution to each well in the microtiterplate. 
3. Cover the microtiterplate with a suitable lid and shake the plate gently for approximately 
30 seconds. 
4. Incubate the microtiterplate for 30 minutes at 37°C. 
5. Let the microtiterplate settle at room temperature. 
6. Remove the lid and analyse the samples using a plate spectrophotometer, Bio Assay 
Reader HTS 7000 (Perkin Elmer), at a wavelength of 570 nm. 
7. Ensure that the standard curve follows a linear line. If not, the protein measurement needs 
to be repeated. 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0 0 s1 s1 s1        
B 125 125 s2 s2 s2        
C 250 250 s3 s3 s3        
D 500 500 s4 s4 s4        
E 750 750 s5 s5 s5        
F 1000 1000 s6 s6 s6        
G 1500 1500 s7 s7 s7        
H   s8 s8 s8        
 
Figure 19: Loading of a 96-well microtiterplate for protein quantification. The standard solutions are added as 
duplicates, 20 µL in each well, and the concentrations are given as µg/mL. The samples are added as triplicates, 5 µL 
in each well. 
 
 
 
 
 
